| abstract |
The present invention relates to novel site-specific pegylated or site-specific lipidated IGF-1 and analogues of IGF-1, e.g., [2-(ethoxyimino(2-carbamate-20K branched PEG))acetyl-Gly 1 , Asn 59 ]hIGF-1(1 -7O)-OH (SEQ ID NO: 106) and [2-(n- octadecoxyimino)acetyl-Gly 1 , Asn 59 ]hIGF- 1 ( 1 -7O)-OH (SEQ ID NO: 109), and the use of said compounds for treatment of IGF-1 -receptor mediated conditions, such as short stature, diabetes therapy, neurodegenerative disease treatment, and cartilage repair. The site- specifically modified IGF-1 and analogues of IGF-1 according to the present invention have improved pharmacokinetic profile, improved biological activity, and/or decreased immunogenicity. |